Physician profile
Hazon Rotbart
NPI 1508428020
$2,113.96
in general payments reported to CMS, 2019-2025
18 companies · $847 in 2025
The $847 reported for 2025 was more than what 85% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $220 · 2023: $396 · 2024: $446 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,689.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $599.10 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $238.70 | 2021-2025 | Farxiga, Lokelma, Wainua |
| Merck Sharp & Dohme LLC | $202.65 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $172.28 | 2022-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $165.27 | 2021-2024 | Lifevest |
| Scpharmaceuticals INC. | $145.68 | 2023-2025 | |
| Amgen INC. | $127.06 | 2021-2022 | |
| Abbott Laboratories | $93.66 | 2025 | Cardiomems |
| Lexicon Pharmaceuticals, INC. | $88.68 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.10 | 2023-2025 | Jardiance |
| Philips North America LLC | $41.69 | 2024 | (5091) Amb Mon & Diag Und |
| Novo Nordisk INC | $41.28 | 2024-2025 | Ozempic |
| Daiichi Sankyo INC. | $23.36 | 2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $23.05 | 2023 | Onpattro |
| Heartflow, INC. | $22.85 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $22.51 | 2021 | |
| Bridgebio Pharma, INC. | $20.93 | 2025 | Attruby |
| Lilly USA, LLC | $19.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazon Rotbart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.